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Introduction {#cam4822-sec-0001}
============

Lung cancer is the leading cause of cancer‐related mortality in China and worldwide [1](#cam4822-bib-0001){ref-type="ref"}. Non‐small‐cell lung cancer (NSCLC) is the most common subtype that accounts for 85% of all lung cancer patients. The majority of NSCLC patients were diagnosed at an advanced tumor stage and lost the opportunity of surgical resection [2](#cam4822-bib-0002){ref-type="ref"}. For more than two decades, platinum‐based combination treatment is a standard treatment for advanced NSCLC. However, the effectiveness has apparently reached a plateau, and the overall survival rate has still been extremely poor. Populations with diverse genetic variations in candidate pathways have been proposed to affect the susceptibility to cancer development, response efficiency to cancer treatment, and survival outcomes for lung cancer patients [3](#cam4822-bib-0003){ref-type="ref"}.

DNA repair capacity (DRC) is a double‐edged sword in the etiology and response to clinical therapies for various cancers. The individual\'s susceptibility to cancer risk can be drastically increased due to defect in DNA repair system [4](#cam4822-bib-0004){ref-type="ref"}, [5](#cam4822-bib-0005){ref-type="ref"}. On the other hand, increased DRC may influence the sensitivity of tumor cells to chemo‐ and radiotherapy and thus affect therapeutic efficacy by permitting cancer cells to fix DNA damages aroused by these agents [5](#cam4822-bib-0005){ref-type="ref"}, [6](#cam4822-bib-0006){ref-type="ref"}. Nucleotide excision repair (NER) and base excision repair (BER) are two major DNA repair pathways those involve coordination of numerous genes. Single‐nucleotide polymorphisms (SNPs) in DNA repair genes may modulate DNA repair capacity via influencing protein expression or activities, and therefore affecting the therapeutic response for lung cancer patients [7](#cam4822-bib-0007){ref-type="ref"}, [8](#cam4822-bib-0008){ref-type="ref"}, [9](#cam4822-bib-0009){ref-type="ref"}, [10](#cam4822-bib-0010){ref-type="ref"}. As a result, identifying special genetic biomarkers in DNA repair pathways to guide personalized therapy strategy may minimize therapy resistance and improve the clinical outcome of NSCLC patients.

Thus, 12 DNA repair genes were chosen for analysis in this study, including nine key processor genes (*RRM1*,*ERCC1*,*ERCC2*,*XPA*,*XPB*,*XPF*,*XPG*,*CSB*, and *DDB2*) in the NER pathway, and three key processor genes (*XRCC1*,*FEN1*, and *APEX1*) from the BER pathway. A total of 17 SNPs (general information shown in Table [1](#cam4822-tbl-0001){ref-type="table-wrap"}) were selected from the above genes and their associations with the overall survival of advanced NSCLC patients were further investigated.

###### 

Selected DNA repair genes and single‐nucleotide polymorphisms in this study

  Pathway                      Gene         SNP        Chr         Chr position[a](#cam4822-note-0002){ref-type="fn"}   Alleles       Function
  ---------------------------- ------------ ---------- ----------- ---------------------------------------------------- ------------- ----------
  Nucleotide excision repair                                                                                                          
  *RRM1*                       rs11030918   11         4094257     T/C                                                  5′near gene   0.302
  rs12806698                   11           4094744    C/A         5′UTR                                                0.227         
  *ERCC1*                      rs11615      19         45420395    C/T                                                  Asn118Asn     0.331
  rs3212986                    19           45409478   G/T         3′UTR                                                0.295         
  *ERCC2*                      rs13181      19         45351661    T/G                                                  Lys751Gln     0.237
  rs50872                      19           45359191   C/T         Intron                                               0.182         
  *XPA*                        rs1800975    9          97697296    G/A                                                  Intron        0.354
  *XPB*                        rs2276583    2          127257108   A/G                                                  3′near gene   0.379
  *XPF*                        rs1799797    16         13920136    T/A                                                  5′near gene   0.220
  *XPG*                        rs17655      13         102875652   G/C                                                  Asp1104His    0.361
  *CSB*                        rs3793784    10         49539493    C/G                                                  5′near gene   0.238
  *DDB2*                       rs2029298    11         47213167    C/T                                                  5′near gene   0.445
  rs3781619                    11           47233766   A/G         Intron                                               0.357         
  Base excision repair                                                                                                                
  *XRCC1*                      rs25487      19         43551574    G/A                                                  Arg399Gln     0.260
  *FEN1*                       rs174538     11         61792609    G/A                                                  5′near gene   0.282
  rs4246215                    11           61796827   G/T         3′UTR                                                0.303         
  *APEX1*                      rs1130409    14         20456995    G/T                                                  Asp148Glu     0.376

dbSNP Chromosome Report, GRCh38.
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Materials and Methods {#cam4822-sec-0002}
=====================

Ethics statement {#cam4822-sec-0003}
----------------

The study subjects provided their written informed consent after a clear explanation of study objective. All subjects were genetically unrelated ethnic Han Chinese and this study was approved by the Institutional Review Board of Tongji Medical College, Huazhong University of Science and Technology.

Study population {#cam4822-sec-0004}
----------------

We recruited 405 lung cancer cases from Wuhan Steel Group/Corporation Staff‐Worker Hospital between January 2003 and December 2010 in Wuhan City, Hubei Province of Central China. After being diagnosed with lung cancer, the patients received treatment at the same hospital until they died from the disease, and more than 98% patients kept good follow‐up. The 280 advanced NSCLC patients who had completed follow‐up and clinical information were included in the survival analysis. The TNM stage classification was evaluated according to the Staging Manual of AJCC/UICC. We followed up the patients through telephone calls every 3 months until 31 December 2010, and acquired date of death from the hospital records and patients' families via the follow‐up telephone calls. We considered patients who were still alive on 31 December 2010 as censored, and calculated the survival time for each patient from the date when patients were confirmed diagnosed of lung cancer until the date of death or the last follow‐up. The large part of the study patients have been published in our previous study [11](#cam4822-bib-0011){ref-type="ref"}.

Written informed consent for storage and use of blood samples, and for obtaining medical records information during follow‐up were provided by all patients. Information on demographic characteristics, tobacco smoking, alcohol consumption, medical history, and family history of cancer were collected through an interview using a pretested questionnaire. Individuals who had smoked \<1 cigarette per day for less than 1 year in their entire lifetime were defined as nonsmokers; those who had stopped smoking for more than 1 year were considered as former smokers; otherwise, those who were still smoking in the previous year were defined as current smokers.

DNA extraction and genotyping {#cam4822-sec-0005}
-----------------------------

Genomic DNA was extracted using the Gentra puregene blood kit (Qiagen, Hilden, Germany) following the manufacturer\'s instructions. In this study, genotyping of SNPs in all subjects were carried out by the TaqMan method using the ABI 7900HT Sequence Detection System (Applied Biosystems). All primers and probes were ordered from Applied Biosystems. The sequences of primers and probes are available in Supplementary Table 1. The cycling conditions were conducted as described in detail previously [11](#cam4822-bib-0011){ref-type="ref"}: 50°C for 2 min, 95°C for 10 min, and followed by 45 cycles of 95°C for 15 sec and 60°C for 1 min. For quality control, we randomly selected 5% samples as repeated trials, and the repeated results were identical as the former results..

Statistical analysis {#cam4822-sec-0006}
--------------------

The Kaplan--Meier method and log‐rank test were used to calculate and compare the median survival time (MST) for patients with different age, gender, smoking status, histology, TNM stage, therapy treatments of surgical resection, chemotherapy, radiotherapy, and different genotypes. The associations between SNPs and death risk of advanced NSCLC patients were estimated using the multivariate Cox regression models, with adjustment of age, smoking status, histology, TNM stage, and therapy treatments of surgical resection, chemotherapy, and radiotherapy. The effect modifications by patient characteristics and clinical features (age, smoking status, histology, TNM stage, and therapy treatment of surgical resection, chemotherapy, and radiotherapy) on the effects of SNPs on death risk of advanced NSCLC patients were assessed using the Wald test in the multivariate Cox proportional hazards regression models after adjusting for the confounders. All analyses were conducted on the SPSS 20.0 software (SPSS Inc., Chicago, IL) and a two‐side *P *\<* *0.05 was considered statistically significant.

Results {#cam4822-sec-0007}
=======

Patient characteristics {#cam4822-sec-0008}
-----------------------

The demographic and clinical characteristics of the 280 advanced NSCLC patients who had completed the follow‐up information are listed in Table [2](#cam4822-tbl-0002){ref-type="table-wrap"}. For these patients, the mean age was 64.28 ± 9.30 years, 214 (76.4%) patients died of lung cancer, 83 (29.6%) received surgical operations, 215 (76.8%) received chemotherapies, and 131 (46.8%) received radiotherapies. The Kaplan--Meier analysis, log‐rank test, and univariate Cox analysis showed that elder patients aged \>65 (MST = 12.2 vs. 17.9, log‐rank *P *=* *0.001) and patients with an advanced stage (MST = 10.8 vs. 16.7 vs. 19.1, log‐rank *P *\<* *0.001) had a significantly shorter MST and an increased risk of death. Similarly, patients who received surgical operation (MST = 16.9 vs. 12.7, Log‐rank *P *=* *0.019) and chemotherapy (MST = 16.0 vs. 11.0, Log‐rank *P *=* *0.035) had more clinical benefit than patients who did not receive surgical operation or chemotherapy, respectively. However, no significant effects were found for gender, smoking status, histological subtype, and radiotherapy on MST and death risk for advanced NSCLC patients.

###### 

Patient characteristics and clinical features

  Variables                                      Lung cancer patients, *n*(%)   Deaths   MST (month)   Log‐rank *P*        HR (95% CI) [a](#cam4822-note-0004){ref-type="fn"}
  ---------------------------------------------- ------------------------------ -------- ------------- ------------------- ----------------------------------------------------
  Age                                                                                                                      
  ≤65                                            136 (48.6)                     98       17.9          0.001               1.00 (Reference)
  \>65                                           144 (51.4)                     116      12.2          1.58 (1.20--2.07)   
  Sex                                                                                                                      
  Male                                           241 (86.1)                     183      13.3          0.089               1.00 (Reference)
  Female                                         39 (13.9)                      31       25.2          0.72 (0.49--1.06)   
  Smoking                                                                                                                  
  Never                                          44 (15.7)                      33       20.7          0.200               1.00 (Reference)
  Former smokers                                 150 (53.6)                     115      13.7          1.42 (0.96--2.10)   
  Current smokers                                86 (30.7)                      66       13.4          1.27 (0.84--1.94)   
  Histology                                                                                                                
  Adenocarcinoma                                 114 (40.7)                     85       17.4          0.054               1.00 (Reference)
  SCC                                            78 (27.9)                      58       16.5          0.90 (0.64--1.25)   
  Others[b](#cam4822-note-0005){ref-type="fn"}   88 (31.4)                      71       10.6          1.40 (0.98--1.84)   
  Stage                                                                                                                    
  IIIA                                           70 (25.0)                      47       19.1          \<0.001             1.00 (Reference)
  IIIB                                           77 (27.5)                      55       16.7          1.27 (0.86--1.87)   
  IV                                             133 (47.5)                     112      10.8          1.92 (1.36--2.70)   
  Surgery                                                                                                                  
  No                                             197 (70.4)                     149      12.7          0.019               1.00 (Reference)
  Yes                                            83 (29.6)                      65       16.9          0.71 (0.53--0.95)   
  Chemotherapy                                                                                                             
  No                                             65 (23.2)                      49       11.0          0.035               1.00 (Reference)
  Yes                                            215 (76.8)                     165      16.0          0.71 (0.52--0.98)   
  Radiotherapy                                                                                                             
  No                                             149 (53.2)                     110      13.3          0.368               1.00 (Reference)
  Yes                                            131 (46.8)                     104      15.3          0.88 (0.68--1.16)   

HR, hazard ratio.

Data were calculated by univariate Cox regression analysis.

Others include large cell, bronchoalveolar, mixed cell, undifferentiated and pathologic, not otherwise specified carcinomas.
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Associations of SNPs and survival of advanced NSCLC patients {#cam4822-sec-0009}
------------------------------------------------------------

As shown in Table [3](#cam4822-tbl-0003){ref-type="table-wrap"}, the Kaplan--Meier method and log‐rank test showed that the advanced patients carrying the *ERCC2* rs50872 CT and CT+TT genotypes had the MST of 18.0 and 17.8 months, respectively, which were significantly longer than the survival time of rs50872 CC genotype carriers (MST = 12.7, log‐rank *P *=* *0.034 and 0.031, respectively) (Fig. [1](#cam4822-fig-0001){ref-type="fig"}). The multivariate Cox regression models revealed that the adjusted hazard ratio (HR) and 95% CI of death risk was 0.72 (0.54--0.97) for rs50872 CT, 0.82 (0.37--1.81) for rs50872 TT, and 0.73 (0.55--0.98) for rs50872 CT+TT genotype, compared with the rs50872 CC genotype (Table [3](#cam4822-tbl-0003){ref-type="table-wrap"}). There was a dose--response effect of the rs50872 T allele in reducing death risk (*P* ~trend~  = 0.018). Meanwhile, the Kaplan--Meier method and log‐rank test showed that the advanced patients carrying the *XRCC1* rs25487 GA and GA+AA genotypes had the MST of 11.2 and 11.7 months, respectively, which were significantly shorter than the survival time of rs25487 GG genotype carriers (MST = 16.7, log‐rank *P *=* *0.038 and 0.048, respectively) (Table [3](#cam4822-tbl-0003){ref-type="table-wrap"}, Fig. [1](#cam4822-fig-0001){ref-type="fig"}). Patients carrying *XRCC1* rs25487 GA+AA genotype had a marginally increased risk of death than those with rs25487 GG genotype \[HR (95% CI) = 1.29 (0.97--1.70)\] (Table [3](#cam4822-tbl-0003){ref-type="table-wrap"}). For all other polymorphisms, we did not find any association of their genotypes with the survival outcomes of advanced NSCLC patients.

###### 

Associations between SNP genotypes and survival of patients with advanced non‐small‐cell lung cancer

  Genes               SNPs                HR (95% CI)[a](#cam4822-note-0007){ref-type="fn"}   *P* [a](#cam4822-note-0007){ref-type="fn"}   Lung cancerpatients (*N* = 280)   Deaths(*n* = 214)   MST(month)   Log‐rank *P*
  ------------------- ------------------- --------------------------------------------------- -------------------------------------------- --------------------------------- ------------------- ------------ --------------
  NER pathway genes                                                                                                                                                                                           
  *RRM1*              rs11030918                                                                                                                                                                              
  TT                  1.00 (Reference)                                                        126 (45.0)                                   98                                16.7                             
  TC                  0.99 (0.74--1.32)   0.928                                               123 (43.9)                                   93                                13.4                0.790        
  CC                  1.06 (0.67--1.70)   0.796                                               30 (10.7)                                    23                                11.7                0.929        
  rs12806698                                                                                                                                                                                                  
  CC                  1.00 (Reference)                                                        133 (47.5)                                   105                               15.8                             
  CA+AA               1.00 (0.78--1.32)   0.993                                               146 (52.2)                                   109                               12.6                0.916        
  *ERCC1*             rs11615                                                                                                                                                                                 
  CC                  1.00 (Reference)                                                        166 (59.3)                                   127                               13.9                             
  CT+TT               0.89 (0.67--1.18)   0.398                                               113 (40.3)                                   87                                13.7                0.895        
  rs3212986                                                                                                                                                                                                   
  GG                  1.00 (Reference)                                                        103 (36.8)                                   80                                13.7                             
  GT                  1.19 (0.87--1.62)   0.283                                               134 (47.9)                                   100                               15.3                0.734        
  TT                  0.97 (0.65--1.46)   0.885                                               42 (15.0)                                    34                                12                  0.494        
  *ERCC2*             rs13181                                                                                                                                                                                 
  TT                  1.00 (Reference)                                                        236 (84.3)                                   179                               13.4                             
  TG+GG               0.89 (0.62--1.28)   0.517                                               43 (15.4)                                    35                                18.4                0.457        
  rs50872                                                                                                                                                                                                     
  CC                  1.00 (Reference)                                                        171 (61.1)                                   138                               12.7                             
  CT                  0.72 (0.54--0.97)   0.032                                               95 (33.9)                                    69                                18.0                0.034        
  TT                  0.82 (0.37--1.81)   0.625                                               13 (4.6)                                     7                                 13.7                0.490        
  CT+TT               0.73 (0.55--0.98)   0.033                                               108 (38.5)                                   76                                17.8                0.031        
                      *P* ~trend~         0.018                                                                                                                                                               
  *XPA*               rs1800975                                                                                                                                                                               
  GG                  1.00 (Reference)                                                        80 (28.6)                                    64                                14.5                             
  GA                  0.95 (0.69--1.31)   0.763                                               133 (47.5)                                   106                               13.4                0.978        
  AA                  0.87 (0.59--1.28)   0.476                                               66 (23.6)                                    44                                17.8                0.427        
  *XPB*               rs2276583                                                                                                                                                                               
  AA                  1.00 (Reference)                                                        97 (34.6)                                    73                                16.5                             
  AG                  1.03 (0.76--1.39)   0.870                                               151 (53.9)                                   118                               12.7                0.183        
  GG                  0.89 (0.55--1.44)   0.647                                               31 (11.1)                                    23                                21                  0.470        
  *XPF*               rs1799797                                                                                                                                                                               
  TT                  1.00 (Reference)                                                        168 (60)                                     130                               14.5                             
  TA+AA               1.20 (0.91--1.60)   0.203                                               111 (39.6)                                   84                                13.7                0.823        
  *XPG*               rs17655                                                                                                                                                                                 
  GG                  1.00 (Reference)                                                        78 (27.9)                                    58                                16.5                             
  GC                  1.17 (0.84--1.63)   0.357                                               144 (51.4)                                   113                               13.3                0.113        
  CC                  1.03 (0.69--1.53)   0.905                                               57 (20.4)                                    43                                14.5                0.550        
  *CSB*               rs3793784                                                                                                                                                                               
  CC                  1.00 (Reference)                                                        135 (48.2)                                   105                               12.7                             
  CG                  0.98 (0.73--1.32)   0.915                                               116 (41.4)                                   87                                14.5                0.654        
  GG                  1.24 (0.77--2.00)   0.375                                               28 (10.0)                                    22                                15                  0.945        
  *DDB2*              rs3781619                                                                                                                                                                               
  AA                  1.00 (Reference)                                                        94 (33.6)                                    74                                14.7                             
  AG                  0.93 (0.69--1.27)   0.659                                               140 (50.0)                                   104                               13.3                0.985        
  GG                  0.88 (0.59--1.32)   0.545                                               45 (16.1)                                    36                                15                  0.813        
  rs2029298                                                                                                                                                                                                   
  CC                  1.00 (Reference)                                                        129 (46.1)                                   102                               13.4                             
  CT                  0.91 (0.68--1.22)   0.511                                               118 (42.1)                                   87                                16.7                0.343        
  TT                  1.03 (0.65--1.62)   0.910                                               32 (11.4)                                    25                                13.3                0.911        
  BER pathway genes                                                                                                                                                                                           
  *XRCC1*             rs25487                                                                                                                                                                                 
  GG                  1.00 (Reference)                                                        159 (56.8)                                   120                               16.7                             
  GA                  1.29 (0.95--1.74)   0.099                                               95 (33.9)                                    75                                11.2                0.038        
  AA                  1.29 (0.77--2.16)   0.341                                               22 (7.9)                                     17                                12.5                0.593        
  GA+AA               1.29 (0.97--1.70)   0.075                                               117 (41.8)                                   92                                11.7                0.048        
  *FEN1*              rs174538                                                                                                                                                                                
  GG                  1.00 (Reference)                                                        108 (38.6)                                   86                                14.2                             
  GA                  1.12 (0.81--1.53)   0.500                                               121 (43.2)                                   92                                13.4                0.698        
  AA                  0.83 (0.55--1.24)   0.368                                               50 (17.9)                                    36                                16.7                0.435        
  rs4246215                                                                                                                                                                                                   
  GG                  1.00 (Reference)                                                        106 (37.9)                                   86                                14.2                             
  GT                  1.11 (0.81--1.52)   0.533                                               119 (42.5)                                   91                                13.4                0.713        
  TT                  0.81 (0.55--1.21)   0.311                                               54 (19.3)                                    37                                17.9                0.390        
  *APEX1*             rs1130409                                                                                                                                                                               
  GG                  1.00 (Reference)                                                        86 (30.7)                                    64                                13.7                             
  GT                  0.91 (0.66--1.25)   0.553                                               144 (51.4)                                   108                               17.0                0.681        
  TT                  1.31 (0.87--1.99)   0.199                                               47 (16.8)                                    40                                10.0                0.267        

HR, hazard ratio; NER, Nucleotide excision repair; BER, base excision repair.

The Cox regression analysis was adjusted for age, sex, smoking status, histology, TNM stage, surgery, chemotherapy, and radiotherapy status. Note: Survival analyses were determined for haplotypes or diplotypes \>10% frequency.
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![Kaplan--Meier survival curves for advanced NSCLC patients by *ERCC2* rs50872 (A) and *XRCC1* rs25487 (B) genotypes. NSCLC, non‐small‐cell lung cancer.](CAM4-5-2332-g001){#cam4822-fig-0001}

Stratification analyses for ERCC2 rs50872 and XRCC1 rs25487 on survival of advanced NSCLC patients {#cam4822-sec-0010}
--------------------------------------------------------------------------------------------------

The advanced NSCLC patients were further stratified by their features of age, smoking status, histology, TNM stage, and therapy treatments. The protective effects of rs50872T allele were more obvious in subjects aged ≤65 years old \[HR (95% CI) = 0.57 (0.37--0.87), *P *=* *0.010\], patients without surgery \[HR (95% CI) = 0.68 (0.47--0.98), *P *=* *0.036\], but who underwent chemotherapy\[HR (95% CI) = 0.64 (0.46--0.91), *P *=* *0.012\] and radiotherapy \[HR (95% CI) = 0.58 (0.38--0.89), *P *=* *0.013\] (Table [4](#cam4822-tbl-0004){ref-type="table-wrap"}).

###### 

Stratification analyses for associations between SNP genotypes and overall survival of advanced non‐small‐cell lung cancer patients

  Variables                                      *ERCC2*‐rs50872CC   *ERCC2‐*rs50872‐CT+TT   *P* ~interaction~ [a](#cam4822-note-0008){ref-type="fn"}   *XRCC1*‐rs25487GG   *XRCC1*‐rs25487‐GA+AA   *P* ~interaction~ [a](#cam4822-note-0008){ref-type="fn"}                                                                                        
  ---------------------------------------------- ------------------- ----------------------- ---------------------------------------------------------- ------------------- ----------------------- ---------------------------------------------------------- ------- ------- --------- ------ -------- ------ ------- ------------------- ------- -------
  Age                                                                                                                                                                                                                                                                  0.314                                                                        0.773
  ≤65                                            81/62               16.7                    54/36                                                      28.1                0.077                   0.57 (0.37--0.87)                                          0.010           77/54     20.7   57/44    15.0   0.121   1.15 (0.76--1.73)   0.516    
  \>65                                           90/76               11.3                    54/40                                                      13.3                0.377                   0.82 (0.55--1.23)                                          0.332           82/66     13.5   60/48    9.5    0.193   1.36 (0.93--1.99)   0.117    
  Sex                                                                                                                                                                                                                                                                  0.816                                                                        0.561
  Male                                           146/116             12.5                    94/67                                                      13.7                0.104                   0.73 (0.54--1.00)                                          0.050           132/98    15.8   105/83   11.1   0.068   1.34 (1.00--1.81)   0.052    
  Female                                         25/22               23.9                    9/14                                                       28.3                0.106                   0.47 (0.18--1.20)                                          0.115           27/22     25.2   12/9     23.9   0.685   1.10 (0.48--2.49)   0.824    
  Smoking                                                                                                                                                                                                                                                              0.770                                                                        0.663
  Never‐smokers                                  24/21               12.7                    147/117                                                    28.9                0.179                   0.50 (0.23--1.10)                                          0.083           27/20     28.9   17/13    8.7    0.157   1.35 (0.57--3.20)   0.499    
  Smokers                                        12/20               12.9                    88/64                                                      13.9                0.088                   0.73 (0.53--1.00)                                          0.053           132/100   15.8   100/79   12.0   0.175   1.27 (0.94--1.72)   0.117    
  Histology                                                                                                                                                                                                                                                            0.154                                                                        0.352
  Adenocarcinoma                                 74/58               15.0                    40/27                                                      21.3                0.088                   0.77 (0.47--1.24)                                          0.279           64/48     18.4   50/37    15.0   0.728   1.02 (0.65--1.59)   0.947    
  SCC                                            47/35               16.5                    31/23                                                      13.7                0.713                   1.18 (0.68--2.02)                                          0.562           48/35     17.9   30/23    12.5   0.046   1.68 (0.91--3.09)   0.095    
  Others[b](#cam4822-note-0009){ref-type="fn"}   50/45               9.6                     37/26                                                      13.3                0.018                   0.50 (0.27--0.91)                                          0.023           47/37     11.3   37/32    9.0    0.349   1.52 (0.92--2.53)   0.103    
  Stage                                                                                                                                                                                                                                                                0.467                                                                        0.136
  IIIA                                           44/31               19.0                    26/16                                                      25.7                0.323                   0.67 (0.33--1.34)                                          0.252           41/24     22.8   29/23    15.0   0.078   1.56 (0.78--3.14)   0.210    
  IIIB                                           51/38               14.5                    25/17                                                      28.1                0.059                   0.65 (0.35--1.20)                                          0.170           43/32     18.4   32/22    13.4   0.125   1.60 (0.88--2.94)   0.125    
  IV                                             76/69               10.6                    57/43                                                      12.6                0.240                   0.76 (0.51--1.14)                                          0.187           75/64     11.7   56/47    10.0   0.798   1.14 (0.76--1.71)   0.535    
  Surgery                                                                                                                                                                                                                                                              0.543                                                                        0.973
  No                                             117/95              12.7                    79/54                                                      13.4                0.088                   0.68 (0.47--0.98)                                          0.036           110/83    15.8   83/64    10.5   0.057   1.40 (0.99--1.97)   0.058    
  Yes                                            54/43               15.0                    29/22                                                      25.7                0.190                   0.82 (0.46--1.47)                                          0.505           49/37     18.0   34/28    13.9   0.378   1.29 (0.76--2.19)   0.343    
  Chemotherapy                                                                                                                                                                                                                                                         0.764                                                                        0.986
  No                                             31/24               11.0                    33/25                                                      10.7                0.663                   0.92 (0.49--1.71)                                          0.793           31/23     12.2   30/24    8.3    0.265   1.62 (0.81--3.27)   0.176    
  Yes                                            140/114             15.0                    75/51                                                      21.7                0.011                   0.64 (0.46--0.91)                                          0.012           128/97    17.9   87/68    12.7   0.117   1.36 (0.99--1.87)   0.059    
  Radiotherapy                                                                                                                                                                                                                                                         0.259                                                                        0.053
  No                                             86/66               14.7                    62/44                                                      11.5                0.659                   0.88 (0.58--1.34)                                          0.555           83/59     17.9   62/49    10.8   0.008   1.77 (1.19--2.63)   0.005    
  Yes                                            85/72               12.0                    46/32                                                      26.3                0.008                   0.58 (0.38--0.89)                                          0.013           76/61     16.0   55/43    12.5   0.796   0.97 (0.65--1.45)   0.888    

The Cox regression analysis was adjusted for age, sex, smoking status, histology, TNM stage, surgery, chemotherapy, and radiotherapy status when appropriate.

Others include large cell, bronchoalveolar, mixed cell, undifferentiated and pathologic, not otherwise specified carcinomas.
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For the *XRCC1* rs25487 polymorphism, the effect of rs25487 GA+AA genotype on elevated death risk of NSCLC patients was significant in the patients without radiotherapy \[HR (95% CI) = 1.77 (1.19--2.63), *P *=* *0.005\]. In addition, the radiotherapy can marginally modify the effect of *XRCC1* rs25487 GA+AA genotype on death risk for advanced NSCLC patients (*P* ~interaction~ = 0.053). We also observed the marginal association between rs25487 GA+AA genotype with the increased death risk for males \[HR (95% CI) = 1.34 (1.00--1.81), *P *=* *0.052\], advanced NSCLC patients without surgery \[HR (95% CI) = 1.40 (0.99--1.97), *P *=* *0.058\] but those who underwent chemotherapy \[HR (95% CI) = 1.36 (0.99--1.87), *P *=* *0.059\] (Table [4](#cam4822-tbl-0004){ref-type="table-wrap"}).

The combinative effects of ERCC2 rs50872 and XRCC1 rs25487 on survival of advanced NSCLC patients {#cam4822-sec-0011}
-------------------------------------------------------------------------------------------------

We stratified the study patients by both *ERCC2* rs50872 and *XRCC1* rs25487 variants. Among patients with *ERCC2* rs50872CC genotype, those with *XRCC1* rs25487 GA+AA genotypes had increased death risk than those with rs25487GG genotype \[HR (95% CI) = 1.67 (1.04--2.68), *P *=* *0.034\]; but among patients with *ERCC2* rs50872CT+TT genotypes, the above effects of *XRCC1* rs25487 GA+AA on death risk for advanced NSCLC patients were eliminated \[HR (95% CI) = 1.06 (0.75--1.50), *P *=* *0.741\]. However, there was no significant interaction between *ERCC2* rs50872 and *XRCC1* rs25487 on death risk for advanced NSCLC patients (*P* ~interaction~ = 0.134). We further analyzed the combinative effects of the two SNPs on the overall survival of advanced NSCLC patients. The Kaplan--Meier method and the Cox regression models showed that the advanced patients carrying the *ERCC2* rs50872 CC genotype in combination with *XRCC1* rs25487 GA+AA genotype had the shortest MST (11.2 month) and worst death risk \[HR (95% CI) = 1.70 (1.15--2.52), *P *=* *0.008\] when compared with those carrying rs50872 CT+TT and rs25487 GG genotype (MST = 22.0 month) (Table [5](#cam4822-tbl-0005){ref-type="table-wrap"})**.**

###### 

The combinative effects of *ERCC2* rs50872 and *XRCC1* rs25487 on the overall survival of advanced non‐small‐cell lung cancer patients

  *ERCC2*rs50872   *XRCC1*rs25487   n~p~/n~d~   MST    Log‐rank *P*   HR(95% CI)[a](#cam4822-note-0011){ref-type="fn"}   *P* [a](#cam4822-note-0011){ref-type="fn"}   HR(95% CI)[a](#cam4822-note-0011){ref-type="fn"}   *P* [a](#cam4822-note-0011){ref-type="fn"}
  ---------------- ---------------- ----------- ------ -------------- -------------------------------------------------- -------------------------------------------- -------------------------------------------------- --------------------------------------------
  CT+TT            GG               69/45       22.0   --             1.00 (Reference)                                   --                                           1.00 (Reference)                                   --
                   GA+AA            37/30       12.6   0.008          1.67 (1.04--2.68)                                  0.034                                        1.67 (1.04--2.68)                                  0.034
  CC               GG               90/75       15.3   0.004          1.00 (Reference)                                   --                                           1.60 (1.09--2.36)                                  0.017
                   GA+AA            80/62       11.2   0.015          1.06 (0.75--1.50)                                  0.741                                        1.70 (1.15--2.52)                                  0.008

MST, median survival time; HR, hazard ratio.

The Cox regression analysis was adjusted for age, sex, smoking status, histology, TNM stage, surgery, chemotherapy, and radiotherapy status.
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Discussion {#cam4822-sec-0012}
==========

This study investigated 13 SNPs in nine NER genes and four SNPs in three BER genes, and found that genetic variations of *ERCC2* and *XRCC1* may play important roles in predicting the overall survival of advanced NSCLC patients in Han Chinese. The *ERCC2* rs50872 T allele was associated with a favorable survival outcome for advanced NSCLC patients, and these effects were mainly seen in male patients, elder patients, and in patients without surgery but who underwent chemotherapy or radiotherapy. However, the *XRCC1* rs25487 A allele was associated with a bad survival outcome for advanced NSCLC patients, and these effects were mainly seen in male patients, and in patients who underwent chemotherapy but without surgery and radiotherapy. The advanced patients carrying the *ERCC2* rs50872 CC genotype in combination with *XRCC1* rs25487 GA+AA genotype had the shortest MST and highest death risk when compared with those carrying rs50872 CT+TT and rs25487 GG genotype. However, no significant associations were found for the other polymorphisms and survival outcomes of advanced NSCLC patients.

Exposure to environmental and endogenous carcinogens such as environmental chemical agents, ultraviolet light, and ionizing radiation can lead to a variety of DNA alterations [12](#cam4822-bib-0012){ref-type="ref"}. Most of these alterations may give rise to genetic instability, mutagenesis, and cell death if the alterations have not been repaired appropriately [12](#cam4822-bib-0012){ref-type="ref"}. DNA repair plays important roles in maintaining genome integrity, preventing carcinogenesis, and interindividual variability in platinum inactivation. The reduced DNA capacity is associated with increased response and improved survival to chemo‐ and radio‐ therapies that act by damaging DNA of cancer cells[13](#cam4822-bib-0013){ref-type="ref"}. Given the possible effects on gene expression, we postulated that genetic polymorphisms of DNA repair genes might influence the individuals' response to cancer therapies. Therefore, it is important to perform a pathway‐based analysis including DNA repair pathways that may affect the efficiency of response to cancer therapy.

NER is the major repair system for removing bulky DNA lesions such as monoadducts, cross‐links, and oxidative damages, especially those caused by cigarette smoking [13](#cam4822-bib-0013){ref-type="ref"}, [14](#cam4822-bib-0014){ref-type="ref"}, [15](#cam4822-bib-0015){ref-type="ref"}, [16](#cam4822-bib-0016){ref-type="ref"}. *ERCC2* is an integral member of the core transcription factor IIH via p44, and the ATP‐dependent DNA helicase activity of *ERCC2* opens the double helix in order to cut the damaged strand and remove the damaged DNA pieces.[13](#cam4822-bib-0013){ref-type="ref"}, [17](#cam4822-bib-0017){ref-type="ref"}, [18](#cam4822-bib-0018){ref-type="ref"}, [19](#cam4822-bib-0019){ref-type="ref"}. One previous study in the Korean population suggested that the *ERCC2* rs50872 TT genotype was associated with a significantly poorer response and a poor prognostic factor in 129 NSCLC patients without surgery but treated with platinum‐based chemotherapy [13](#cam4822-bib-0013){ref-type="ref"}. This was the only study ever published about the *ERCC2* rs50872 polymorphism and lung cancer prognosis. However, on the contrary, our study suggested that the *ERCC2* rs50872 T allele was associated with a favorable prognosis for advanced NSCLC patients. These inconsistent results may be due to the patients' heterogeneity and different social status between their study patients and ours.

A total of four SNPs in three BER genes were evaluated. The *XRCC1* protein is an important component of the BER pathway, which fixes base damage and DNA single‐strand breaks caused by ionizing radiation, alkylating agents, and oxidative damage [20](#cam4822-bib-0020){ref-type="ref"}, [21](#cam4822-bib-0021){ref-type="ref"}. Although its functional effect has not been well known, rs25487 G\>A (R399Q), occurs in the poly (ADP‐ribose) polymerase binding domain of *XRCC1* gene, may affect complex assembly, and reduce DNA repair efficiency [22](#cam4822-bib-0022){ref-type="ref"}. In our study, we found that the *XRCC1* rs25487 A allele was associated with a bad survival outcome for advanced NSCLC patients. This result was consistent with the latest meta‐analysis in 2012, which used 22 articles, that suggested *XRCC1* rs25487 GA and AA genotypes could influence overall survival of lung cancer patients \[GA vs. GG: HR (95% CI) = 1.23 (1.06--1.44); AA vs. GG: HR (95% CI) = 2.03 (1.20--3.45)\] [23](#cam4822-bib-0023){ref-type="ref"}. Moreover, one study accomplished in Shenyang, China found the adjusted HRs for *XRCC1* rs25487 GA and AA genotype were 1.28 and 2.68 in 257 nonsmoking female lung adenocarcinoma patients, respectively [24](#cam4822-bib-0024){ref-type="ref"}. Two additional studies also reported *XRCC1* rs25487 A allele was associated with shorter MSTs and higher death risk [25](#cam4822-bib-0025){ref-type="ref"}, [26](#cam4822-bib-0026){ref-type="ref"}.Our study provided the consistent results supporting the reliability of results from the above studies.

The unfavorable effect of *XRCC1* rs25487 A allele was mainly seen among male patients and patients who underwent chemotherapy but without surgery and radiotherapy. One study reported that *XRCC1* rs25487 A allele was associated with poor prognosis in stage II‐IIIA and among older individuals [27](#cam4822-bib-0027){ref-type="ref"}. However, three studies carried out in 161 advanced NSCLC patients [5](#cam4822-bib-0005){ref-type="ref"} and 82 advanced NSCLC patients [28](#cam4822-bib-0028){ref-type="ref"} who underwent platinum‐based chemotherapy, as well as in 74 advanced NSCLC patients treated with platinum‐based chemotherapy and additionally received concomitant or sequential radiotherapy [29](#cam4822-bib-0029){ref-type="ref"}, respectively, failed to identify significant associations between *XRCC1* rs25487 and survival outcomes. These inconsistent results may be due to their smaller sample sizes and the differences in specific stage, pathology, and therapy among patients in different studies.

In our study, no significant associations were found for *RRM1* variants (rs11030918 and rs12806698) and survival outcomes of advanced NSCLC patients. This result was consistent with two studies in Korea of 158 never‐smokers with NSCLC [25](#cam4822-bib-0025){ref-type="ref"} and 298 advanced NSCLC patients [30](#cam4822-bib-0030){ref-type="ref"}, as well as one study in China of 340 NSCLC patients [31](#cam4822-bib-0031){ref-type="ref"}, respectively. The latest meta‐analysis in 2012 using 10 cohort studies with a total of 1252 NSCLC patients assessed that neither *ERCC1* rs3212986 nor rs11615 variant had any influence on survival outcomes of platinum‐based treatment among advanced NSCLC patients [32](#cam4822-bib-0032){ref-type="ref"}. Another meta‐analysis in 2011 including 17 studies also found that neither *ERCC1* (rs3212986 and rs11615) nor *ERCC2* (rs13181) was significantly associated with response and progression‐free survival in NSCLC patients [33](#cam4822-bib-0033){ref-type="ref"}. Our study provided the similar negative associations between above variants and survival of advanced NSCLC patients. No significant correlations with survival outcomes were found in two studies for *XPA* rs1800975 [34](#cam4822-bib-0034){ref-type="ref"}, [35](#cam4822-bib-0035){ref-type="ref"} and nine studies for *XPG* rs17655 [26](#cam4822-bib-0026){ref-type="ref"}, [27](#cam4822-bib-0027){ref-type="ref"}, [29](#cam4822-bib-0029){ref-type="ref"}, [31](#cam4822-bib-0031){ref-type="ref"}, [34](#cam4822-bib-0034){ref-type="ref"}, [35](#cam4822-bib-0035){ref-type="ref"}, [36](#cam4822-bib-0036){ref-type="ref"}, [37](#cam4822-bib-0037){ref-type="ref"}, [38](#cam4822-bib-0038){ref-type="ref"}, respectively. Our study provided the similar results. However, two studies indicated *XPA* rs1800975 GA/AA was significantly associated with poor NSCLC survival [29](#cam4822-bib-0029){ref-type="ref"}, [39](#cam4822-bib-0039){ref-type="ref"}. Additionally, no published investigations had provided clues among *XPB* (rs2276583), *XPF* (rs1799797), *CSB* (rs3793784), *DDB2* (rs3781619 and rs2029298), *FEN1* (rs174538 and rs4246215), *APEX1* (rs1130409) and the survival outcomes in NSCLC patients. The results of the above investigations suggested that there were inconsistent observations between different studies, and the reasons may be explained by the diversity of genetic background between Caucasians and Asians, different specific stage, pathology, and therapy and sample sizes.

There were several strengths in our study. Firstly, all lung patients were staff members of Wuhan Iron and Steel (Group) Corporation, who had a similar economic status, a better medical compliance, and high follow‐up rate (98%). Secondly, this study included 13 SNPs in nine NER genes and four SNPs in three BER genes for analysis, and all of them are important components in DNA repair pathways. However, some limitations of this study should not be neglected. Firstly, we used a moderate sample sized advanced NSCLC patients in the survival analysis, and additional studies with larger population were needed for further validation. In addition, because of lacking functional assays, the underlying biologic mechanisms for the observed positive SNPs are still unclear and need further investigation.

In conclusion, our study provided preliminary evidence that the *ERCC2* rs50872 T allele was associated with a favorable survival while the *XRCC1* rs25487 A allele was associated with a worse survival outcome for advanced NSCLC patients. Furthermore, advanced NSCLC patients carrying the *ERCC2* rs50872 C in combination with *XRCC1* rs25487 A allele rendered the shortest MST and highest death risk for advanced NSCLC patients. Additional studies carried out in lung cancer patients with specific stage, pathology, and therapy, as well as functional biological studies need to be validated for potential associations.
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